Phase 1b study of marizomib (MRZ) in combination with temozolomide (Temodar) and radiation in newly diagnosed, Grade 4 malignant glioma
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Marizomib (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 21 Sep 2017 Number of arms changed from 3 to 4,hence planned patient number also changed from 48 to 60.
- 21 Sep 2017 Planned number of patients changed from 48 to 60.
- 24 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.